Hero in the field
How Guinea beat the tsetse fly
Dr. Mamadou Camara helped lead the fight against the insect that transmits sleeping sickness.

The first sleeping sickness patient that Dr. Mamadou Camara ever diagnosed and treated was brought to him tied up. He’d become so agitated that people around him thought he’d gone mad or been cursed by someone practicing witchcraft; they didn’t know what else to do.
A year later, a healthy young man walked up to greet him, but Mamadou had no idea who he was. Someone had to tell him: “That's Barry!”
“That is one of the most dramatic aspects of the disease,” said Mamadou. “It takes away your human soul.”
Mamadou is Guinea’s national coordinator for neglected tropical diseases (NTDs), and he’s spent more than 30 years fighting sleeping sickness. In January 2025, the World Health Organization confirmed that Guinea had eliminated the disease as a public health problem—the first NTD the country had ever beaten. A lot of people made that possible, but few have been at it as long as Mamadou.
A parasite in the brain
Sleeping sickness—also known as human African trypanosomiasis (HAT)—is caused by a specific type of trypanosome parasite, carried by tsetse flies, that gets transmitted to people when the flies bite. There are two forms of the disease, but Guinea’s, called gambiense, is the most common. At first, it manifests a lot like malaria with fever, headaches, and exhaustion. But once the parasite crosses into the brain, behavior starts to change. People become confused and agitated, and many begin sleeping during the day and lying awake at night, which is how the disease got its name. Without treatment, it leads to psychosis and eventually death.
One of the crueler parts of sleeping sickness is that late-stage patients don’t normally know they’re sick. “A person with trypanosomiasis is heartbreaking to see,” Mamadou said. “The disease eats away at them, and yet they are not aware of it.”
The disease that came back
Guinea has beaten sleeping sickness once before. At least the country thought it had. Campaigns to control the disease in the middle of the last century brought the number of cases down so much that by the 1960s, people believed the disease was gone. The programs to fight it were shut down. Unfortunately, the parasite kept circulating under the radar, and in the early 1990s, it resurfaced.
At the time, Mamadou was trained as a malaria specialist. But when an international aid program asked him to assess the growing number of sleeping sickness cases, he answered the call. Between 1992 and 1998, he and his colleagues mapped the disease across the whole country.
That survey became the foundation for Guinea’s national program, which Mamadou has run ever since.
A fight on two fronts
Under Mamadou’s leadership, Guinea attacked sleeping sickness from two directions. The first priority was to test and treat anyone who was infected. Mobile teams were set up that went village by village, often staying overnight in the places they were screening to gain the trust of locals.
The second priority was to go after the parasite-carrying tsetse flies.
That required figuring out where they actually were. Mamadou’s team started by looking in the places that textbooks said tsetse flies live—along forested riverbanks—but they found almost none. Then, villagers who knew the area well pointed them to the mangroves, where people fished, cut wood, and harvested salt. The first time Mamadou went in, he said, “I was attacked by flies and could not believe it.”
With that information in hand, the team constructed small blue panels of fabric treated with insecticide to lure tsetse flies out and kill them. Working with researchers in Burkina Faso, they eventually shrank those insecticide traps down to a fraction of their original size, without making them less effective. Villagers were skeptical at first, but they soon noticed they no longer had to carry brooms to swat flies away. “Now it is the community itself that asks for them,” Mamadou said.
When the Ebola epidemic hit Guinea in 2014, screening and treatment for sleeping sickness stopped. In the country’s Boffa district, that led to two very different outcomes. In villages where insecticide traps had already been set up, no new cases were found once testing resumed. But in nearby villages without the traps, as many as one in 20 people were infected.
From arsenic to a single dose
When Mamadou started working on sleeping sickness, the main treatment for late-stage infection was melarsoprol, an arsenic-based drug given by painful injection. It was so toxic that it killed about one in twenty of the patients it was supposed to save. “I was more worried that the patient would die in my hands,” Mamadou said, “than I was reassured by the treatment itself.”
But breakthroughs over the past 15 years have brought radical improvements. First came NECT, a safer combination therapy, and then fexinidazole, a 10-day course of pills. And now there’s acoziborole, which was just approved for use this year and cures the disease with one oral dose of just three pills. (The Gates Foundation is one of the funders of the Drugs for Neglected Diseases initiative, which developed acoziborole with Sanofi. Sanofi will donate it to the WHO so patients can get it for free, as it has done with earlier sleeping sickness treatments.)
Not done yet
Mamadou is proud of what Guinea has accomplished, but he hasn’t forgotten the past. “The victory is there; it is a fact,” he said. “But we do not want a repeat of the victory of the 1960s.”
His next goals are to get acoziborole to patients across Guinea; to fold sleeping sickness work into the fight against other neglected diseases like leprosy and Buruli ulcer, which are still factors in Guinea; and to train the people who will take over from him. Four members of his program have finished PhDs, and more are working on master’s degrees.
When my team told Mamadou the title of this profile series, called Hero in the Field, he pushed back. “Mamadou is not the hero,” he said. “It is this entire community.”
I think he’s being too modest. Mamadou has spent more than three decades traveling to villages with no roads, and paying out of his own pocket to get patients treatment. His rule, he said, has always been to “live for [fighting] trypanosomiasis, not live off trypanosomiasis.” He hopes the country reaches zero transmission by 2030. And if it takes longer? Mamadou says he’ll be there, even if he’s using a walking stick, to greet the team that finishes the job.


